CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

Despite remarkable success in the treatment of hematological malignancies, CAR T-cell therapies for solid tumors have floundered, in large part due to local immune suppression and the effects of prolonged stimulation leading to T-cell dysfunction and exhaustion. One mechanism by which gliomas and ot...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Immunother Cancer
Hauptverfasser: Choi, Bryan D., Yu, Xiaoling, Castano, Ana P., Darr, Henia, Henderson, Daniel B., Bouffard, Amanda A., Larson, Rebecca C., Scarfò, Irene, Bailey, Stefanie R., Gerhard, Genevieve M., Frigault, Matthew J., Leick, Mark B., Schmidts, Andrea, Sagert, Jason G., Curry, William T., Carter, Bob S., Maus, Marcela V.
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2019
Schlagworte:
Short Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6857271/
https://ncbi.nlm.nih.gov/pubmed/31727131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0806-7
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge